RAPID TEST SYSTEM FOR MYCOBACTERIAL SUSCEPTIBILITY

对耐多药结核病的控制受到严重阻碍 缺乏快速的抗菌药物敏感性测试方法， 分枝杆菌感染的诊断。这项研究提供了一个 一种快速抗生素敏感性测试的新方法， Cell Systems的专有微滴技术。单个分枝杆菌 小菌落将被封装并在非常小的克隆中生长， 由凝胶微滴（GMD）限定的区域。GMD的自动分析， 流式细胞术，克隆生长和荧光染色后， 生物体构成了该测定系统的基础。易感性 分枝杆菌抗生素已被发现在5天内使用GMD- 克隆生长法，从而证明了这种方法的基本可行性 approach.第一阶段研究的目标是开发定量的 分枝杆菌生长和耐药性的评价方法 抗菌剂。这些实验将成为 商业上可行的快速分枝杆菌检测系统，利用 传统的方法在微尺度上。结核病的重新出现， 美国的一个公共卫生问题表明， 这样的测试系统。

The control of multidrug resistant tuberculosis has been severely hampered by the lack of rapid methods for antimicrobial susceptibility testing and diagnosis of mycobacterial infection. The research proposed provides a novel approach to rapid antibiotic susceptibility testing, based on One Cell Systems' proprietary microdrop technology. Individual mycobacterial microcolonies will be encapsulated and grown within a very small cloning region defined by a gel microdrop (GMD). Automated analysis of GMDs by flow cytometry following clonal growth and fluorescent staining of the organisms forms the basis of this assay system. Susceptibility of mycobacteria to antibiotics has been detected in 5 days using the GMD- clonal growth method, thus demonstrating the basic feasibility of this approach. The goals of the Phase I research are to develop quantitative methods for evaluation of mycobacterial growth and resistance to antimicrobial agents. These experiments will form the basis for a commercially viable, rapid mycobacterial assay system, utilizing conventional methods at a microscale. The re-emergence of tuberculosis as a public health problem in the United States points to the urgent need for such a testing system.